The interest of tobramycin, studied here in 63 cases of severe infection, is due to several factors: --its ease of use including in cases of renal insufficiency; --the efficiency of subcutaneous administration, of particular interest to patients on anticoagulants; --its action on multi-resistant Enterobacteria and those not responding to gentamicin. Antibiotherapy is however only one of the elements of success in the treatment of severe infections, beside two factors which are often linked and determining: early treatment and the development of foci resistant to antibiotics.